Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 8/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31159179 | 1.00 | PDK2 (0.46) | PDK2GPR119MAPK1GRM5GRM1 | |
| SCHEMBL31159118 | 0.90 | PDK2 (0.43) | PDK2GPR119MAPK1GRM5GRM1 | |
| SCHEMBL14660533 | 0.90 | RORC (0.45) | PDK2GPR119KDM1ARORC | |
| SCHEMBL1329957 | 0.89 | GPR119 (0.44) | PDK2GPR119MAPK1GRM5GRM1 | |
| SCHEMBL1513306 | 0.86 | PDK2 (0.49) | PDK2GPR119KDM1ARORCMEN1 | |
| SCHEMBL31158780 | 0.86 | PDK2 (0.43) | PDK2GPR119MAPK1GRM5GRM1 | |
| SCHEMBL24771292 | 0.86 | GPR119 (0.42) | PDK2GPR119MAPK1GRM5GRM1 | |
| SCHEMBL1311605 | 0.84 | GRIN2B (0.44) | PDK2GPR119MAPK1GRM5GRM1 | |
| SCHEMBL15713358 | 0.83 | PDK2 (0.43) | PDK2GPR119MAPK1KDM1ARORC | |
| SCHEMBL15689748 | 0.83 | STS (0.44) | PDK2GPR119MAPK1KDM1ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| EP-2342194-B1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-9630949-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-04-25 | — | — | US | disclosed |
| US-9458132-B2 | Therapeutic compounds and compositions and their use as PKM2 modulators | AGIOS PHARMACEUTICALS, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458132-B2 | Therapeutic compounds and compositions and their use as PKM2 modulators | AGIOS PHARMACEUTICALS, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458132-B2 | Therapeutic compounds and compositions and their use as PKM2 modulators | AGIOS PHARMACEUTICALS, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150307473-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307473-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307473-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2015-10-29 | — | — | US | disclosed |
| CN-104387372-A | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV | 2015-03-04 | — | — | CN | disclosed |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-12 | — | — | US | disclosed |
| US-8871187-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereon in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-28 | — | — | US | disclosed |
| WO-2014074848-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | disclosed |
| CN-102203081-A | Oxoazetidine derivatives, method for the production thereof and use thereof in human medicine and cosmetics | GALDERMA RES & DEV | 2011-09-28 | — | — | CN | disclosed |
| EP-2342194-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010052253-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307473-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS | PDK1, PDK2, PDK3 | PDK2 2/4885GPR119 117/4885MAPK1 578/4885 |
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | CYP2D6, CYP51A1, CYP2C19 | PDK2 744/4885GPR119 702/4885MAPK1 2822/4885 |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | CYP51A1, TYR, CYP2C19 | PDK2 658/4885GPR119 742/4885MAPK1 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.